Analysis of failed therapy evaluations in radioembolization of primary and secondary liver cancers.
Max MasthoffPhilipp SchindlerFabian HardersWalter HeindelChristian WilmsHartmut H SchmidtAndreas PascherLars SteggerKambiz RahbarMichael KöhlerMoritz WildgruberPublished in: Journal of cancer research and clinical oncology (2020)
A substantial number of patients are precluded from TARE following 99mTc-MAA evaluation, which is, therefore, implicitly needed to determine contraindications to TARE and should not be refrained from in pretreatment process. However, a preceding careful patient selection is needed especially in patients with high hepatic tumor burden and alteration in lab parameters.